ArticleDigestive diseases and sciences2025
EphA3/EFNA3 Reverse Signalling Promotes Epithelial-to-Mesenchymal Transition via ERK Pathway to Facilitate Colorectal Cancer Metastasis.
Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated multi-omics and machine learning identify EFNA3 as a key biomarker of tumor invasion.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
BACKGROUND AND
aimsLiver metastasis significantly contributes to poor survival in patients with colorectal cancer (CRC), posing therapeutic challenges due to limited understanding of its mechanisms. We aimed to identify a potential target critical for CRC liver metastasis.
methodsWe analyzed the Gene Expression Omnibus (GEO) and the Cancer Genome Atlas (TCGA) databases and identified EphrinA3 (EFNA3) as a potential clinically relevant target. The interacting proteins of EFNA3 were investigated by co-immunoprecipitation. The role of EphA3/EFNA3 axis were examined using EFNA3 knockdown and overexpressed CRC cells by transwell, wound healing, cell viability, colony formation and apoptosis assays, as well as subcutaneous and spleen injection tumour models in nude mice.
resultsEFNA3 expression was significantly higher in CRC tissues than in para-carcinoma tissues, and elevated in metastatic tissues compared to primary CRC tissues. Higher EFNA3 was significantly correlated with advanced tumour stages and unfavourable clinical outcomes in CRC patients. Functional assays suggested that EFNA3 knockdown inhibited the migration, invasion and proliferation of CRC cells both in vitro and in vivo, while EFNA3 overexpression had opposite effects. Mechanistically, EphA3 was confirmed to bind to EFNA3, and EphA3/EFNA3 reverse signalling was found to promote epithelial-to-mesenchymal transition (EMT) by activating extracellular signal-regulated kinase (ERK) 1/2 signalling, thereby promoting metastasis.
conclusionOur findings suggest that EFNA3 promotes CRC metastasis, and that EphA3/EFNA3 signalling may promote EMT by activating the ERK signalling. These results indicate that the EphA3/EFNA3 axis could be a potential target for metastatic CRC.
Indexed as
Identifiers
40928719What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.